NYSE:STESteris Stock Price, Forecast & News

Steris' stock was trading at $145.25 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, STE stock has increased by 3.4% and is now trading at $150.22. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Steris in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Steris.

Steris is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Steris.

Steris PLC (NYSE:STE) announced its quarterly earnings data on Wednesday, May, 13th. The medical equipment provider reported $1.64 EPS for the quarter, beating analysts' consensus estimates of $1.57 by $0.07. The medical equipment provider earned $822.99 million during the quarter, compared to analysts' expectations of $788.37 million. Steris had a net margin of 13.45% and a return on equity of 16.34%. During the same period last year, the company posted $1.53 earnings per share. View Steris' earnings history.

Steris announced a quarterly dividend on Wednesday, May 13th. Investors of record on Friday, June 12th will be paid a dividend of $0.37 per share on Friday, June 26th. This represents a $1.48 dividend on an annualized basis and a yield of 0.99%. The ex-dividend date of this dividend is Thursday, June 11th. View Steris' dividend history.

3 brokers have issued 1-year price objectives for Steris' stock. Their forecasts range from $170.00 to $170.00. On average, they expect Steris' share price to reach $170.00 in the next twelve months. This suggests a possible upside of 13.2% from the stock's current price. View analysts' price targets for Steris.

Media headlines about STE stock have trended somewhat positive on Friday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Steris earned a media sentiment score of 1.2 on InfoTrie's scale. They also assigned press coverage about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about Steris.

Steris saw a decrease in short interest in June. As of June 30th, there was short interest totaling 1,240,000 shares, a decrease of 8.8% from the June 15th total of 1,360,000 shares. Based on an average daily trading volume, of 672,600 shares, the days-to-cover ratio is currently 1.8 days. Approximately 1.5% of the shares of the stock are sold short. View Steris' Current Options Chain.

Some companies that are related to Steris include Abbott Laboratories (ABT), Medtronic (MDT), Becton Dickinson and (BDX), Stryker (SYK), Intuitive Surgical (ISRG), Boston Scientific (BSX), Baxter International (BAX), Edwards Lifesciences (EW), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), Hologic (HOLX), Insulet (PODD) and Masimo (MASI). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Steris investors own include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Home Depot (HD), Mastercard (MA), AT&T (T), Abbott Laboratories (ABT), Cisco Systems (CSCO), Gilead Sciences (GILD) and Mcdonald's (MCD).

Steris trades on the New York Stock Exchange (NYSE) under the ticker symbol "STE."

Steris' stock is owned by many different institutional and retail investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.49%), State of Alaska Department of Revenue (0.05%), Carnegie Capital Asset Management LLC (0.04%), Mount Yale Investment Advisors LLC (0.03%), Addenda Capital Inc. (0.01%) and Deane Retirement Strategies Inc. (0.01%). Company insiders that own Steris stock include Cary L Majors, Cynthia L Feldmann, Daniel A Carestio, Jacqueline B Kosecoff, John Adam Zangerle, Karen L Burton, Kathleen Bardwell, Loyal W Wilson, Michael B Wood, Michael J Tokich, Mohsen Sohi, Renato Tamaro, Richard Martin Steeves, Walter M Rosebrough Jr and Walter M Rosebrough, Jr. View institutional ownership trends for Steris.

STE stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Fulton Bank N. A., Deane Retirement Strategies Inc., and Addenda Capital Inc.. Company insiders that have sold Steris company stock in the last year include Cary L Majors, Daniel A Carestio, John Adam Zangerle, Mohsen Sohi, Renato Tamaro, Richard Martin Steeves, and Walter M Rosebrough Jr. View insider buying and selling activity for Steris.

STE stock was acquired by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., Mount Yale Investment Advisors LLC, Contravisory Investment Management Inc., Canandaigua National Corp, Private Trust Co. NA, Forte Capital LLC ADV, Park National Corp OH, and Carnegie Capital Asset Management LLC. View insider buying and selling activity for Steris.

Shares of STE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of STE stock can currently be purchased for approximately $150.22.

Steris has a market capitalization of $12.76 billion and generates $3.03 billion in revenue each year. The medical equipment provider earns $407.61 million in net income (profit) each year or $5.64 on an earnings per share basis. Steris employs 13,000 workers across the globe.

The official website for Steris is www.steris.com.

Steris' mailing address is 70 Sir John Rogerson`s Quay, Dublin L2, D02 R296. The medical equipment provider can be reached via phone at 353-1232-2000 or via email at [email protected]